Background: Previous pharmacologic and molecular studies suggest that the ␣ 2 -adrenoceptor subtype A is the target for spinally administered ␣ 2 -adrenergic agonists, i.e., clonidine, for pain relief. However, intrathecally administered ␣ 2 C antisense oligodeoxynucleotide was recently reported to decrease antinociception induced by clonidine in the rat, suggesting non-A sites may be important as well. The current study sought to determine the subtype of ␣ 2 adrenoceptors activated by clonidine in a rodent model for human postoperative pain, and to examine its interaction with spinal cholinergic receptors.
THE ␣ 2 -adrenoceptor agonists unquestionably yield antinociception in acute and in chronic pain states, both in animals and humans. [1] [2] [3] However, ␣ 2 -adrenoceptor agonists, such as dexmedetomidine or clonidine, also produce sedation and cardiovascular depression after systematic or intrathecal injection, limiting their use to an adjuvant for analgesia. Among these compounds, 2-(2,6diethylphenylamino)-2-imidazoline (ST91), a polar analog of clonidine, seems to be an attractive alternative to current agents since it produces analgesia in normal rats and in rats after nerve injury without significant hypotension, bradycardia, and sedation. 4 The favorable profile of ST91 could reflect altered distribution due to its hydrophilicity or due to receptor subtype selectivity. 5 ST91 interacts with different ␣ 2 -adrenoceptors than does clonidine or dexmedetomidine, as indicated by its reversal by antagonists that do not affect these agonists 6 and by its synergy for antinociception when combined with these agonists. 7 We have recently shown that, after peripheral nerve injury, Sprague-Dawley rats manifest remarkable changes in spinal ␣ 2 -adrenoceptor agonist pharmacology for antinociception. First, we showed that the antinociceptive effect of clonidine in normal rats reflects activation of both ␣ 2 A and ␣ 2 non-A-adrenoceptor subtypes, whereas following spinal nerve ligation in animals, this effect is totally due to activation of ␣ 2 non-A-adrenoceptor subtypes. 8 Second, in animals with peripheral injury, but not in normal animals subjected to a noxious thermal stimulus (unpublished observations, Xavier Paqueron, MD, Research Fellow, Department of Anesthesiology, Wake Forest University School of Medicine, June, 2000), clonidine loses its antinociceptive effect after destruction or antagonism of the cholinergic receptor population when the animals were subjected to a mechanical stimulus. 9 This indicates a major shift in ␣ 2 -adrenoceptor mechanisms after nerve injury.
Hypersensitivity to mechanical stimuli following surgery exhibits unique pharmacology of inhibition compared with that of inflammation or nerve injury. The purpose of the current study was to evaluate the potency and efficacy of spinally administered ST91 in an experimental model for human postoperative pain when compared to clonidine. In addition, we examined which of the ␣ 2 -adrenoceptor subtypes was activated by spinally injected clonidine and whether ␣ 2 -adrenoceptor efficacy required interactions with spinal nicotinic and muscarinic receptors after surgery.
Materials and Methods

Surgical Preparation
The study was approved by the Animal Care and Use Committee of the Wake Forest University School of Medicine (Winston Salem, NC to 8.5-cm Tygon ® external tubing (Saint-Gobain Performance Plastics, Akron, OH) was inserted during halothane anesthesia, as previously described. 10 The catheter was passed caudally from the cisterna magnum to the level of lumbar enlargement (7.5-8.0 cm). Only animals without evidence of neurologic dysfunction after catheter insertion were studied. Correct position of the lumbar catheter was verified in a subset (n ϭ 68) of animals after surgery. All studies were performed at least 7 days after insertion of the intrathecal catheter. Paw incision was performed as described by Brennan et al. 11 Animals were anesthetized with halothane; the plantar surface of the left hind paw was prepared with 70% ethanol; and a 1-cm longitudinal incision was made through the skin and fascia, starting 0.5 cm from the edge of the heel and extending toward the toes. The plantaris muscle was elevated and incised longitudinally. The wound was closed with two silk 5.0 sutures.
Behavioral Testing
For determining withdrawal threshold, rats were placed individually in plastic cages with a plastic mesh floor. Animals were tested after acclimation to the environment, typically 30 min after being placed in the cage. Withdrawal threshold to punctuate mechanical testing was determined using calibrated von Frey filaments (Stoelting, Wood Dale, IL), beginning with the 2.0-gauge filament. Filaments were applied vertically to an area adjacent to the wound at the heel for 4 s while the hair was bent. Brisk withdrawal or paw flinching was considered a positive response. In the absence of a response, the filament of next greater force was applied. In the presence of a response, the filament of next lower force was applied. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the updown method, as described by Chaplan et al. 12 Tests were performed in duplicate, with an approximate 3-min test-free period between withdrawal responses, and their average was used. Studies were performed on the first day after paw incision surgery.
Experimental Treatments and Drugs and Their Administration
All drugs experimental treatment was carried out 24 h after plantar incision.
The ␣ 2 -adrenoceptor agonists used in this study were clonidine hydrochloride (non ␣ 2 -adrenoceptor subtype selective, molecular weight of 267 g/mol, nonsubtype selective; Sigma Chemical, St. Louis, MO) and ST91 hydrochloride (␣ 2 non-A preferring, molecular weight of 254 g/mol; Boehringer Ingelheim, Ridgefield, CT). Animals received cumulative dosing at 40-min intervals of intrathecal clonidine (19, 56, 190 nmol) or at 60-min intervals of intrathecal ST91 (20, 59, 197 nmol) . Timing of cumulative injections and dose range were determined in pilot experiments with each drug. Dose-response curves were constructed after conversion of withdrawal thresholds to percent maximum possible effect. Percent maximum possible effect was defined as: 100 ϫ (postdrug response Ϫ baseline)/(prepaw incision threshold Ϫ baseline). Agonists were administered intrathecally in volumes of 10 l, and thresholds for withdrawal were determined 40 min after clonidine administration and 60 min after ST91 injection.
The ␣ 2 -adrenoceptor subtype antagonists were BRL44408, selective for the ␣ 2 -A-adrenoceptor subtype, and ARC239, selective for ␣ 2 -non-A-adrenoceptor subtypes (both from Tocris Cockson, Ballwin, MO). Antagonists or vehicles were injected intrathecally in a volume of 10 l 15 min prior to agonist administration. Based on pilot experiments, we used probe doses of 94 nmol clonidine (25 g) and 59 nmol ST91 (15 g), and doses of 9.4 or 94 nmol BRL (n ϭ 7-10 animals) and of 9.4 or 94 nmol ARC (n ϭ 5-9 animals). All studies were conducted with the investigator blinded to antagonist or vehicle administered. Drugs were dissolved in normal saline or, when necessary, in 2-hydroxypropyl-␤-cyclodextrin (Sigma Chemical).
Muscarinic and nicotinic cholinergic receptor antagonism was performed with intrathecal injection of atropine sulfate (44 nmol) and mecamylamine hydrochloride (491 nmol). We have previously shown that the intrathecal doses of selected antagonists inhibit corresponding cholinergic and ␣ 2 -adrenoceptor ligands in rats subjected to mechanical stimuli. 8, 13 Statistical Analysis Data are represented as mean Ϯ SD. Dose-dependence of clonidine and ST91 was evaluated by linear regression analysis. Paw withdrawal thresholds in response to mechanical stimulation before and after paw incision were compared using a paired Student t test. Effects of individual drugs on withdrawal thresholds were determined using a two-way analysis of variance for repeated measures followed by the Bonferroni correction for appropriate multiple comparisons. P Ͻ 0.05 was considered significant.
Results
One hundred eighty-nine rats were included in the study. The average withdrawal threshold to punctuate mechanical stimulus before paw incision surgery was 40 Ϯ 14 g and decreased to 4 Ϯ 3 g within 24 h after plantar incision (P Ͻ 0.05).
Antihypersensitivity Effect of Clonidine and ST91 in
Rats after Plantar Incision ST91 produced antihypersensitivity to von Frey filaments with similar potency but significantly greater efficacy than clonidine ( fig. 1 ). ST91 produced transient serpentine tail movements, which were no longer present when withdrawal thresholds were evaluated. Larger doses of clonidine could not be studied due to intense behavioral sedation.
␣2-Adrenoceptor Antagonism of Clonidine and ST91 in Rats after Plantar Incision
Intrathecal injection of 94 nmol of clonidine increased the withdrawal threshold significantly 40 min after injection (figs. 2A and 2B). Intrathecal injection of BRL44408 and ARC239 significantly inhibited the antihypersensitivity effect of intrathecal clonidine in a dose-dependent manner (figs. 2A and 2B).
Intrathecal injection of 59 nmol ST91 significantly increased the withdrawal threshold 60 min after injection ( fig. 3A and B ). Intrathecal injection of ARC239 inhibited the antihypersensitivity effect of intrathecal ST91 in a dose-dependent manner (fig. 3A) . In contrast, intrathecal injection of BRL44408 failed to influence the antihypersensitivity effect of ST91 ( fig. 3B ). Intrathecal injection of vehicle or either antagonist alone did not alter the withdrawal threshold (control time points: figs. 2 and 3).
Cholinergic Receptor Antagonist Effects of Clonidine and ST91 in Rats after Plantar Incision
Intrathecal injection of 94 nmol of clonidine increased the withdrawal threshold significantly 40 min after injection ( fig. 4A ). Intrathecal injection of atropine sulfate and mecamylamine significantly inhibited the antihypersensitivity effect of intrathecal clonidine ( fig. 4A ).
Intrathecal injection of 59 nmol ST91 increased the withdrawal threshold significantly 60 min after injection ( fig. 4B ). Neither intrathecal injection of atropine nor of mecamylamine altered the antihypersensitivity effect of intrathecal ST91 ( fig. 4B ). Intrathecal injection of vehicle or either antagonist alone failed to alter the withdrawal threshold (control time points: fig. 4 ).
Discussion
Anesthesiologists deal most commonly with acute pain associated with surgery. Despite the continuing evidence that most patients after surgery experience episodes of severe pain, 14 which can lead to development of chronic pain, 15 most pain research focuses on chronic inflammatory, metabolic, or neuropathic pain conditions. Seminal work by Brennan et al. describing the behavioral, 11 neurophysiologic, 16 and pharmacologic 17 consequences and properties of surgery clearly indicate that postoperative pain differs in many fundamental ways from these other conditions, and we and others have argued that the relative lack of basic research in this area hampers better treatment for our postoperative patients. 18 The current study uses the method developed by Brennan et al. 11, 16, 17 and carries important implications for drug development and drug mechanisms.
Fig. 2. Effect of intrathecal pretreatment with vehicle BRL44408 (␣ 2 A-subtype-preferring antagonist) (A, top) and ARC239 (␣ 2 non-A subtype preferring antagonist) (B, bottom) on withdrawal thresholds before and after paw incision and after in-
Antinociceptive Potency of Intrathecal Clonidine Varies across Pain States
Like opioids, cyclooxygenase inhibitors, and glutamate receptor antagonists, the analgesic potency and maximum efficacy of intrathecal or epidural clonidine depends heavily on the type of clinical pain it is used to treat. This was first noted when the bolus or continuous infusion doses of epidural or intrathecal clonidine to effectively treat neuropathic pain 19 were found to be less than 25% those needed to treat postoperative 20 -22 or obstetricpain. 23 Similarly, potency of clonidine to reduce experimentally induced allodynia was increased compared to treatment of acute noxious stimuli in normal volunteers, 24 indicating a shift in drug action or mechanism in the presence of central sensitization. These clinical observations are paralleled in studies with rodents, where generation of hypersensitivity from nerve injury increases potency and efficacy of intrathecal clonidine. 25, 26 The current study in rats suggests that hypersensitivity to mechanical stimuli surrounding a skin incision lies closer in this regard to the normal condition than that following nerve injury. Intrathecal clonidine's potency in the current study of postoperative hypersensitivity is similar to that observed in rats to acute noxious stimuli. 27
Fig. 3. Effect of intrathecal pretreatment with vehicle ARC239 (␣ 2 non-A-subtype-preferring antagonist) (A, top) and BRL44408 (␣ 2 A-subtype-preferring antagonist) (B, bottom) on withdrawal thresholds before and after paw incision and after intrathecal injection of 59 nmol ST91. Each symbol represents
the mean ؎ SD of 5-9 animals. *P < 0.05 versus preincision and control times; †P < 0.05 versus vehicle; $P < 0.05 versus 0.94 nmol ARC. ST91 (B, bottom) . Each symbol represents the mean ؎ SD of 7-10 animals. *P < 0.05 versus preincision and control times; †P < 0.05 versus vehicle.
Fig. 4. Effect of intrathecal pretreatment with vehicle, atropine (a muscarinic cholinergic receptor antagonist), and mecamylamine (a nicotinic cholinergic receptor antagonist) on withdrawal thresholds before and after paw incision and after intrathecal injection of 94 nmol clonidine (A, top) and of 59 nmol
␣ 2 -Adrenoceptor Pharmacology of Intrathecal Clonidine Varies across Pain States
All three ␣ 2 -adrenoceptor subtypes (A, B, and C) are present in rat spinal cord, 28 with a preponderance of ␣ 2 A and ␣ 2 C subtypes. 29 Anatomic and pharmacologic evidence suggests a shift in analgesic mechanisms of intrathecal clonidine from ␣ 2 A predominant in the normal rat to ␣ 2 C predominant after nerve injury. In the normal rat, antinociception of clonidine is reduced by acute knockdown of ␣ 2 A adrenoceptors using antisense oligodeoxynucleotides 30 and reversed by the ␣ 2 A adrenoceptor preferring antagonist, BRL44408. 8 Following nerve injury there is a loss of ␣ 2 A adrenoceptor immunoreactivity in the spinal cord, but no change or an increase in ␣ 2 C adrenoceptor immunoreactivity, 31 and antinociception of clonidine in this case is unresponsive to antagonism by BRL44408, but reversed by the ␣ 2 non-A-adrenoceptor antagonist, ARC239. 8 The current study suggests that the mix of ␣ 2 -adrenoceptor subtypes responsible for clonidine antinociception following surgery is intermediate between that in the normal animal and that in the neuropathic animal. Thus, BRL44408 reversed clonidine's effect in the current study, indicating a role for ␣ 2 A adrenoceptors, unlike the results after nerve injury. ARC239 was similarly potent to BRL44408 to reverse clonidine's effect in normal animals, 8 but was nearly 10-fold more potent to reverse clonidine's effect after surgery in the current study, indicating a partial, but not complete shift to an ␣ 2 non-A-adrenoceptor mechanism.
Reliance of Intrathecal Clonidine on Spinal Cholinergic Systems Varies across Pain States
Stimulation of spinal cholinergic systems by intrathecal injection of ␣ 2 -adrenoceptor agonists is widely documented in humans and animals. Thus, intrathecal clonidine increases acetylcholine concentrations in cerebrospinal fluid 32 and analgesic effect of clonidine is potentiated by intrathecal neostigmine in humans. 33 The reliance of antinociception from clonidine on this spinal cholinergic interaction varies between normal and nerve-injured animals. Thus, intrathecal clonidine antinociception to acute noxious thermal stimuli in normal rats is unaffected by intrathecal atropine or mecamylamine (unpublished observations, Xavier Paqueron, M.D., Research Fellow, Department of Anesthesiology, Wake Forest University School of Medicine, June 2000), but the reversal of hypersensitivity by clonidine following spinal nerve ligation is completely blocked by intrathecal atropine and partially blocked by intrathecal mecamylamine. 13 The current study suggests that postoperative hypersensitivity most resembles nerve injury-induced hypersensitivity in this regard since the effect of clonidine was completely antagonized by atropine and partially by mecamylamine. Should these data apply to humans, they provide a rationale for the study of epi-dural clonidine-neostigmine combinations for postoperative analgesia.
ST91 Antinociception Reflects Different
Pharmacology from Clonidine ST91, the diethyl derivative of clonidine, was described more than 25 yr ago to explain the lack of hypotensive and sedative properties of clonidine when administered systemically, originally ascribed to its hydrophilic nature. 34 Shortly thereafter, it was demonstrated to produce antinociception after intrathecal injection in rats, 35 but with a different structure activity relation for blockade by ␣ 2 -adrenoceptor antagonists than clonidine or dexmedetomidine, 6, 36 and with differential cross-tolerance with these agents, 37 suggesting it acted on different ␣ 2 -adrenoceptor subtypes. More recent observations of synergistic interactions between dexmedetomidine and ST91 reinforce these early studies. 7 As in normal animals and those with spinal nerve ligation-induced hypersensitivity, 8 the effect of ST91 after surgery in the current study was reversed by the ␣ 2 non-A-adrenoceptor antagonist ARC239 but was unaffected by the ␣ 2 A-adrenoceptor-preferring antagonist BRL44408 or the cholinergic antagonists.
ST91 could represent an improvement on clonidine in the treatment of postoperative pain. Although ST91 exhibits less intrinsic activity than clonidine or dexmedetomidine in normal rats, 38 it is more effective than dexmedetomidine for antinociception in some strains of rats and in some thermal assays. 7 ST91 was more efficacious than clonidine in the current study, although whether this was due to a partial agonist effect of clonidine could not be determined, due to dose-limiting sedation by this agent. Sedation and hypotension limit the use of clonidine in the treatment of postoperative pain. 39 ST91 does not cause sedation after systemic or intrathecal administration, nor does it reduce blood pressure after intrathecal administration in several species. 5, 34, 35, 40 Of course, human trials must await proper preclinical chemistry, formulation, stability, toxicity, and neurotoxicity studies.
In summary, intrathecal clonidine partially reverses the reduced withdrawal threshold to mechanical stimulation near a paw incision in rats through the actions of ␣ 2 A-and ␣ 2 non-A-adrenoceptor subtypes. This is also a mechanism that involves stimulation of spinal cholinergic receptors. These data suggest that the proportion of ␣ 2 -adrenoceptor subtypes activated by clonidine to produce antinociception in the postoperative state differs from the normal animal with acute noxious stimuli and the nerve-injured animal with hypersensitivity. ST91 was more efficacious than clonidine, perhaps because larger relative doses could be administered without sedation, and it relied entirely on ␣ 2 non-A-adrenoceptor subtypes. These data add to the growing literature indicating that postoperative pain exhibits a unique pharma-cology of analgesia compared with acute experimental or chronic nerve injury pain. The data also provide the rationale for the clinical study of epidural clonidineneostigmine combinations and for development of ST91 for clinical trials.
